vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and ACME UNITED CORP (ACU). Click either name above to swap in a different company.
ACME UNITED CORP is the larger business by last-quarter revenue ($52.3M vs $32.6M, roughly 1.6× ASCENTAGE PHARMA GROUP INTERNATIONAL).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
AAPG vs ACU — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $52.3M |
| Net Profit | $11.4M | $985.0K |
| Gross Margin | 90.7% | 39.7% |
| Operating Margin | — | 3.3% |
| Net Margin | — | 1.9% |
| Revenue YoY | — | 13.8% |
| Net Profit YoY | — | -40.4% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $52.3M | ||
| Q4 25 | — | $47.5M | ||
| Q3 25 | — | $49.1M | ||
| Q2 25 | $32.6M | $54.0M | ||
| Q1 25 | — | $46.0M | ||
| Q4 24 | — | $45.9M | ||
| Q3 24 | — | $48.2M | ||
| Q2 24 | — | $55.4M |
| Q1 26 | — | $985.0K | ||
| Q4 25 | — | $1.9M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $11.4M | $4.8M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $4.5M |
| Q1 26 | — | 39.7% | ||
| Q4 25 | — | 38.2% | ||
| Q3 25 | — | 39.1% | ||
| Q2 25 | 90.7% | 41.0% | ||
| Q1 25 | — | 39.0% | ||
| Q4 24 | — | 38.7% | ||
| Q3 24 | — | 38.5% | ||
| Q2 24 | — | 40.8% |
| Q1 26 | — | 3.3% | ||
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 11.5% |
| Q1 26 | — | 1.9% | ||
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 8.8% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | 8.0% |
| Q1 26 | — | $0.24 | ||
| Q4 25 | — | $0.46 | ||
| Q3 25 | — | $0.46 | ||
| Q2 25 | — | $1.16 | ||
| Q1 25 | — | $0.41 | ||
| Q4 24 | — | $0.43 | ||
| Q3 24 | — | $0.54 | ||
| Q2 24 | — | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.2M |
| Total DebtLower is stronger | — | $33.0M |
| Stockholders' EquityBook value | — | $116.7M |
| Total Assets | — | $195.2M |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.2M | ||
| Q4 25 | — | $3.6M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $3.8M |
| Q1 26 | — | $33.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $116.7M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | $115.8M | ||
| Q2 25 | — | $113.7M | ||
| Q1 25 | — | $108.3M | ||
| Q4 24 | — | $107.0M | ||
| Q3 24 | — | $106.3M | ||
| Q2 24 | — | $104.0M |
| Q1 26 | — | $195.2M | ||
| Q4 25 | — | $171.0M | ||
| Q3 25 | — | $173.0M | ||
| Q2 25 | — | $170.9M | ||
| Q1 25 | — | $163.0M | ||
| Q4 24 | — | $162.2M | ||
| Q3 24 | — | $165.5M | ||
| Q2 24 | — | $173.5M |
| Q1 26 | — | 0.28× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
ACU
Segment breakdown not available.
